Related Experiment Video
Updated: Mar 8, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Interference with Tim-3 protein expression attenuates the invasion of clear cell renal cell carcinoma and aggravates
Muming Yu1, Bin Lu1, Yancun Liu1
1Emergency Department, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China.
Abstract:
Tumor cells resistant to anoikis are considered to be candidates for metastasis. In the present study, the role of Tim‑3 in anoikis and its influence on the invasion of clear cell renal cell carcinoma (ccRCC) was investigated. Here, polyhydroxylethylmethacrylate (poly‑HEMA) was applied to two ccRCC cell lines, 786‑O and Caki‑2, to induce detachment from the extracellular matrix (ECM). Tim‑3 mRNA and protein expression levels were assayed by reverse transcription-quantitative polymerase chain reaction (RT‑qPCR) and western blot, respectively. Anoikis was measured by Ho33342/PI double staining, acridine orange staining, and further determined using the CytoSelect™ 24‑well Anoikis Assay kit. Apoptosis was measured using flow cytometry, E‑cadherin and N‑cadherin protein expression were determined using western blotting and a Chemicon cell invasion assay kit was used to quantify the invasive capacity of 786‑O and Caki‑2 cells. It was demonstrated that detachment from the ECM decreases transcription and the protein expression level of Tim‑3 in 786‑O and Caki‑2 cells compared with control cells. Interference with Tim‑3 expression using small interfering RNA exacerbated anoikis in 786‑O and Caki‑2 cells induced by poly‑HEMA treatment. E‑cadherin upregulation, N‑cadherin downregulation, and ECM detachment‑induced reduction in invasion ability were all exacerbated by knockdown of Tim‑3. In conclusion, interference with Tim‑3 expression may attenuate the invasion of renal cell carcinoma by aggravating anoikis, indicating Tim‑3 as a potential therapeutic target for treating ccRCC.
Insights
Tumor cells resistant to anoikis can metastasize. This study shows that inhibiting Tim-3 in clear cell renal cell carcinoma (ccRCC) enhances anoikis, reducing tumor cell invasion and suggesting Tim-3 as a therapeutic target.
Area of Science:
- Oncology
- Cell Biology
- Cancer Metastasis
Background:
- Anoikis resistance is a hallmark of metastatic cancer.
- Clear cell renal cell carcinoma (ccRCC) poses a significant health challenge.
- The role of T-cell immunoglobulin and mucin-domain containing-3 (Tim-3) in ccRCC metastasis requires further elucidation.
Purpose of the Study:
- To investigate the role of Tim-3 in anoikis.
- To determine the influence of Tim-3 on clear cell renal cell carcinoma (ccRCC) cell invasion.
- To explore Tim-3 as a potential therapeutic target for ccRCC.
Main Methods:
- Utilized polyhydroxylethylmethacrylate (poly-HEMA) to induce anoikis in ccRCC cell lines (786-O and Caki-2).
- Assessed Tim-3 expression via RT-qPCR and Western blot.
- Quantified anoikis, apoptosis, E-cadherin, N-cadherin, and cell invasion using various assays, including flow cytometry and cell invasion kits.
Main Results:
- Extracellular matrix (ECM) detachment reduced Tim-3 expression in ccRCC cells.
- Small interfering RNA (siRNA) mediated Tim-3 knockdown exacerbated anoikis and reduced invasion.
- Tim-3 interference led to E-cadherin upregulation and N-cadherin downregulation.
Conclusions:
- Tim-3 expression is linked to anoikis resistance and invasion in ccRCC.
- Interfering with Tim-3 can enhance anoikis and attenuate ccRCC cell invasion.
- Tim-3 represents a promising therapeutic target for ccRCC treatment.
More Related Videos
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
Related Concept Videos
The Tumor Microenvironment
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Inhibition of Cdk Activity